Friday, November 22, 2024 11/22/2024

Understanding Viral Suppression for Newly Diagnosed HIV+ Men to Inform Implementation of TasP and U=U

Award Number: R01AI150502
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary Gay and bisexual men and other sexual minority men (SMM) in the U.S. are burdened by a high and disproportionate rate of HIV infection. Improving outcomes of the HIV Care Continuum through to maintaining viral load (VL) suppression is associated with a significant reduction in the sexual transmission of HIV and significantly better long-term health outcomes. However, little research provides insight into the preventable structural, psychosocial, and behavioral factors that influence durable VL suppression during early infection that can be used in developing effective early intervention strategies. Moreover, the successful implementation of TasP and U=U messaging is a necessary component of the strategy to end the HIV epidemic, but rigorous research is needed to address real-world implementation issues, including safety concerns and perceived barriers among key stakeholder populations. We aim to address these issues with two studies grounded in the Social Ecological Model (SEM) to simultaneously examine both VL suppression and implementation barriers surrounding U=U from multiple levels of influence. Specifically, Aim 1 of the study is to examine time to initial VL suppression and patterns in VL rebound to better understand the dynamic nature of VL suppression and use the SEM along with an intersectional minority stress framework to longitudinally investigate structural, psychosocial, and behavioral factors associated with VL suppression among SMM to better understand risk and resilience. Next, Aim 2 is to examine how adherence and perceived VL status are associated with objective VL status and whether concordance between perceived and actual VL suppression influences sexual risk compensation as captured by event-level sexual behaviors and STI infections. Finally, Aim 3 is designed to understand ongoing barriers to implementing U=U from the perspectives of the three populations critical to its successful implementation among SMM—namely, SMM living with HIV, HIV-negative SMM, and HIV care providers. To do so, Study 1 (Aims 1 and 2) will leverage two LITE cohorts to recruit 250 SMM newly diagnosed with HIV during the course of the studies—we will follow these men for two years immediately following diagnosis, collecting home-based dried blood spot for VL on a monthly basis to examine the dynamic nature of VL suppression. In addition to VL and self-reported data, the study will include objective indicators of adherence and care engagement as well as qualitative interviews. The goal of Study 1 will be to identify risk and resilience factors that influence VL suppression and can be used to guide future intervention development (Aim 1) while simultaneously addressing understudied safety concerns of implementing U=U with regard to unintended risks (Aim 2). In Study 2 (Aim 3), we will use focus groups conducted three times over five years to inform implementation of U=U messaging. Achieving the aims of the proposed study will provide key insights that will be critical for translating to or adapting interventions to enhance their potency and durability and improve the health of SMM living with HIV and curb new infections.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $1,102,831 )
2024	2024	WHITMAN-WALKER INSTITUTE INC	1525 14TH ST NW	WASHINGTON	DC	20005	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	000	5	3/1/2024	NON-COMPETING CONTINUATION	$992,548
2024	2024	WHITMAN-WALKER INSTITUTE INC	1525 14TH ST NW	WASHINGTON	DC	20005	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	001	5	5/23/2024	NON-COMPETING CONTINUATION	$110,283
														Subtotal = $1,102,831

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	000	4	3/13/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $1,120,727 )
2022	2022	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	004	4	3/7/2022	NON-COMPETING CONTINUATION	$293,391
2022	2022	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	001	4	3/1/2022	NON-COMPETING CONTINUATION	$1,115,927
2022	2022	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	005	4	3/7/2022	NON-COMPETING CONTINUATION	-$293,391
2022	2021	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	000	3	2/25/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$4,800
2022	2021	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	003	2	3/7/2022	NON-COMPETING CONTINUATION	-$262,245
2022	2021	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	007	3	3/15/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2022	2021	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	006	3	3/7/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$293,391
2022	2020	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	002	1	3/7/2022	NEW	-$31,146
														Subtotal = $1,120,727

Issue Date FY: 2021 ( Subtotal = $1,052,014 )
2021	2021	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	001	2	8/18/2021	NON-COMPETING CONTINUATION	-$789,769
2021	2021	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	002	3	8/18/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$789,769
2021	2021	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	000	2	3/1/2021	NON-COMPETING CONTINUATION	$1,052,014
														Subtotal = $1,052,014

Issue Date FY: 2020 ( Subtotal = $946,936 )
2020	2020	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	000	1	3/23/2020	NEW	$946,936
														Subtotal = $946,936

Grand Total All Awards = $4,222,508

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Understanding Viral Suppression for Newly Diagnosed HIV+ Men to Inform Implementation of TasP and U=U

Award Number: R01AI150502

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer